CAMK2G and hydrops fetalis: Although CaMKII is proposed to be a novel therapeutic target for HF and HF-related ventricular arrhythmias [17-21], due to the ubiquitous distribution of CaMKII and lack of cardiac specific CaMKII inhibitor, the pharmacological CaMKII inhibition is actually not clinically applicable.